title: Sustained pain-related depression of behavior: effects of intraplantar formalin and complete freund's adjuvant on intracranial self-stimulation (ICSS) and endogenous kappa opioid biomarkers in rats.
abstract: BACKGROUND
  Intraplantar administration of complete Freund's adjuvant (CFA) and formalin are two noxious stimuli commonly used to produce sustained pain-related behaviors in rodents for research on neurobiology and treatment of pain. One clinically relevant manifestation of pain is depression of behavior and mood. This study compared effects of intraplantar CFA and formalin on depression of positively reinforced operant behavior in an assay of intracranial self-stimulation (ICSS) in rats. Effects of CFA and formalin on other physiological and behavioral measures, and opioid effects on formalin-induced depression of ICSS, were also examined.
  
  
  RESULTS
  There were four main findings. First, consistent with previous studies, both CFA and formalin produced similar paw swelling and mechanical hypersensitivity. Second, CFA produced weak and transient depression of ICSS, whereas formalin produced a more robust and sustained depression of ICSS that lasted at least 14 days. Third, formalin-induced depression of ICSS was reversed by morphine doses that did not significantly alter ICSS in saline-treated rats, suggesting that formalin effects on ICSS can be interpreted as an example of pain-related and analgesic-reversible depression of behavior. Finally, formalin-induced depression of ICSS was not associated with changes in central biomarkers for activation of endogenous kappa opioid systems, which have been implicated in depressive-like states in rodents, nor was it blocked by the kappa antagonist norbinaltorphimine.
  
  
  CONCLUSIONS
  These results suggest differential efficacy of sustained pain stimuli to depress brain reward function in rats as assessed with ICSS. Formalin-induced depression of ICSS does not appear to engage brain kappa opioid systems.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Leitl
authors.forename: David N
authors.initials: DN
authors.lastname: Potter
authors.forename: Kejun
authors.initials: K
authors.lastname: Cheng
authors.forename: Kenner C
authors.initials: KC
authors.lastname: Rice
authors.forename: William A
authors.initials: WA
authors.lastname: Carlezon
authors.affiliation: Department of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N, 12th St,, PO Box 980613 Richmond, VA, USA. ssnegus@vcu.edu.
authors.forename: S Stevens
authors.initials: SS
authors.lastname: Negus
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001835:Body Weight / Q000502:physiology; D003216:Conditioning, Operant / Q000187:drug effects; D004195:Disease Models, Animal; D005557:Formaldehyde / Q000633:toxicity*; D005620:Freund's Adjuvant / Q000633:toxicity*; D006930:Hyperalgesia / Q000188:drug therapy / Q000503:physiopathology; D007266:Inhibition, Psychological; D008297:Male; D009020:Morphine / Q000494:pharmacology / Q000627:therapeutic use; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy / Q000523:psychology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000378:metabolism*; D012653:Self Stimulation / Q000187:drug effects*
chemical_list: D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D017473:Receptors, Opioid, kappa; D005557:Formaldehyde; C051844:norbinaltorphimine; D009271:Naltrexone; D009020:Morphine; D005620:Freund's Adjuvant